MicroRNA 452 (miR-452)

MicroRNA 452 (miR-452; also known as MIR452 or hsa-miR-452) is a short, endogenously encoded non-coding RNA of approximately 22 nucleotides that regulates gene expression post-transcriptionally by binding to target mRNAs and promoting their degradation or translation inhibition[1][2]. It is encoded on the Xq28 region in humans and is clustered with MIR224 within the GABRE gene. MiR-452 participates in diverse biological processes, notably influencing cell proliferation, migration, angiogenesis, myogenic differentiation, and tumorigenesis. Its activity is highly context-dependent and can function either as a tumor suppressor or an oncogene depending on the cellular environment and cancer type. In colorectal cancer, miR-452 is upregulated and suppresses VEGFA-mediated signaling, affecting angiogenesis and early tumor growth[1]. In myogenic cells, it promotes proliferation and impedes differentiation by targeting ANGPT1[3]. MiR-452 is a potential biomarker for cancer diagnosis and prognosis and a putative therapeutic target in oncology, though as of now, there are no direct drug interventions targeting this microRNA in clinical use[1][2][3].

Other names

hsa-miR-452MIRN452MIR452hsa-mir-452mir-452

Not drug-mediated; regulates target gene expression via binding to the 3′ UTR of mRNAs, leading to mRNA degradation or translational repression—e.g., downregulates VEGFA, ANGPT1, SOX7